DY131 (GSK 9089) is a selective agonist of the ERRβ/γ receptor with EC50 of 130 nM, does not affect the ERRα, ERα and β (IC50>30 uM).
DY131 inhibits growth in a diverse panel of breast cancer cell lines, causing cell death that involves the p38 stress kinase pathway and a bimodal cell cycle arrest.
DY131 potentiate the ERRgamma-induced growth inhibition in LNCaP-ERRgamma and DU145-ERRgamma cells in a dose-dependent manner.
